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InhibitorObservations that Glioma-associated transcription factors Gli1 andGli2 (Gli1/2), executers of the Sonic Hedgehog
(Shh) signaling pathway and targets of the Transforming Growth Factor β (TGF-β) signaling axis, are involved in
numerous developmental and pathological processes unveil them as attractive pharmaceutical targets. Unc-51-
like serine/threonine kinase Ulk3 has been suggested to play kinase activity dependent and independent roles in
the control of Gli proteins in the context of the Shh signaling pathway. This study aimed at investigatingwhether
the mechanism of generation of Gli1/2 transcriptional activators has similarities regardless of the signaling
cascade evoking their activation. We also elucidate further the role of Ulk3 kinase in regulation of Gli1/2 proteins
and examine SU6668 as an inhibitor of Ulk3 catalytic activity and a compound targeting Gli1/2 proteins in
different cell-based experimental models. Here we demonstrate that Ulk3 is required not only for maintenance
of basal levels of Gli1/2 proteins but also for TGF-β or Shh dependent activation of endogenous Gli1/2 proteins
in human adipose tissue derived multipotent stromal cells (ASCs) and mouse immortalized progenitor cells,
respectively. We show that cultured ASCs possess the functional Shh signaling axis and differentiate towards
osteoblasts in response to Shh. Also, we demonstrate that similarly to Ulk3 RNAi, SU6668 prevents de novo
expression of Gli1/2 proteins and antagonizes the Gli-dependent activation of the gene expression programs
induced by either Shh or TGF-β. Our data suggest SU6668 as an efﬁcient inhibitor of Ulk3 kinase allowing
manipulation of the Gli-dependent transcriptional outcome.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Misregulation of cellular signaling pathways, that are important in
embryonic development and maintaining adult homeostasis, leads to
inherited as well as sporadic diseases. One of such pathways, where a
clear correlation between abnormal pathway activation and disease
progression has been observed, is the Sonic Hedgehog (Shh) signaling
pathway [1]. Disruption or misregulation of the Shh pathway results in
various developmental abnormalities including holoprosencephaly,
Pallister–Hall syndrome, Gorlin syndrome, Greig cephalopolysyndactyly,se tissue derived stromal cells;
L, full-length Gli proteins; Ptch,
mo, Smoothened; shRNA, short
Suppressor of Fused; TGF-β,
se 3; WB, Western blot; HSC,
time PCR
se 4, Tallinn 12618, Estonia.
. Open access under CC BY license.Rubinstein–Taybi syndrome anddifferent types of cancer (basal cell carci-
noma, medulloblastoma, glioma, breast, pancreatic, prostate cancers
and more). Similarly important is the TGF-β signaling pathway, with
its role in various types of cancer, vascular diseases and ﬁbrosis [2,3].
The Shh pathway utilizes Gli proteins (Gli1, 2, 3) as transcriptional
effectors. According to the widely accepted paradigm, differentiated
regulation of Gli proteins occurs in an Hh signal dependent way. In the
absence of the ligand, Gli1 is transcriptionally repressed; full-length
Gli2 and Gli3 (Gli2/3FL) proteins are bound by a putative cytoplasmic
complex called Hedgehog signaling complex (HSC). HSC may consist
of a number of proteins including Suppressor of Fused (Sufu), kinesin-
like protein Kif7, unc-51-like kinase 3 (Ulk3), and Gli2/3FL transcription
factors [4–8]. Gli2/3FL proteins bound by HSC are phosphorylated for
degradation and processing into the transcriptional repressor forms
(Gli2/3REP) [9–12]. Activation of Shh pathway leads to rapid stabiliza-
tion and activation of Gli2/3FL probably through yet uncharacterized
phosphorylation events, their relocation to the nucleus and up-
regulation of their target genes, for instance Ptch1 and self-amplifying
Gli1 [7,12]. Gli2 has been also suggested as a transcriptional target of
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Although both proteins, Gli2 and Gli3, may be involved in primary me-
diation of Shh activities, the role of Gli2 activator ismore crucial, where-
as Gli3 acts mainly as a transcriptional repressor [14–16].
Gli proteins are known to be regulated independently of Hh ligands
on both transcriptional and post-translational levels.MouseGli1 protein
can be activated via Erk1/2 kinases, andGli2 is shown to beup-regulated
in the epidermis of mice over-expressing TGF-β1 [17,18]. Also, the
TGF-β1/SMAD3/TCF4/β-catenin signaling axis controls human GLI2,
and consequently GLI1, expression [18,19]. Regulation of Gli2 in bone
metastases and tumor-induced osteolysis also occurs independently of
the canonical Shh pathway [20].
Most of the smallmolecule inhibitors of the Shhpathway identiﬁed so
far target trans-membrane SMO oncoprotein responsible for triggering
the intracellular signaling cascade following the ligandbinding to another
trans-membrane protein PTCH1. In addition, several inhibitors of GLI
proteins and Shh itself have been identiﬁed (reviewed in Ref. [21]).
However, no inhibitors targeting the activity of either HSC complex or
protein kinases required for activation of GLI proteins have been report-
ed. The latter might be effective not only in Shh pathway inhibition, but
also in alleviating TGF-β/GLI dependent signaling events.
SU6668 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
2,4-dimethyl-1H-pyrrole-3-propanoic acid; TSU68) has been shown to
inhibit several tyrosine and serine/threonine protein kinases in an ATP
competitive manner [22,23]. The afﬁnity chromatography experiment
using a resin covalently boundwith SU6668 has revealed that addition-
ally to the previously known targets, SU6668 is capable to bind a num-
ber of other protein kinases including ULK3 [23]. We have recently
identiﬁed Ulk3 as an important Gli regulator. However, a mechanism
of regulation of the Ulk3 gene and possible interrelations between
endogenous Ulk3 and Gli proteins remains unclear.
Adipose tissue derived stromal cells (ASCs, also known as mesen-
chymal stem or progenitor cells) have been extensively investigated
during the last decade. These heterogeneous cell populations have
evoked a great interest for regenerative medicine due to their non-
immunogenic phenotype and capacity to respond to appropriate in-
ducers by increasing expression of markers speciﬁc for different
mesodermal lineages, such as adipocytes, chondrocytes or osteoblasts
[24–26]. The Shh signaling pathway has not been extensively charac-
terized in human ASCs, although one research group has reported
that activation of Shh signaling negatively regulates differentiation
of ASCs towards osteoblasts triggered by osteogenic cocktail [27].
However, these studies were conducted using Shh-conditional
media or SMO agonists added to ASCs in the presence of osteogenic
inductors, whereas inﬂuence of Shh itself on native ASCs has not
been analyzed. In contrast, the osteogenic capacity of Shh in mouse
ASCs and C3H10T1/2 is well documented [28,29]. Differentiation of
osteoprogenitors occurs under control of Runx2, a factor essential
for bone formation and skeletal development [30,31]. Runx2 is
expressed from two alternative promoters at least in two isoforms.
Both Runx2 isoforms are expressed in osteoblasts and participate in
differentiation [30,32]. Osteogenesis is characterized by expression
of lineage-speciﬁc proteins, such as early markers Sp7 and alkaline
phosphatase (AP) and late markers osteopontin (Opn) and
osteocalcin (Bglap) [29,33,34]. Gli2/3 proteins as mediators of Hh ac-
tivities participate not only in positive regulation of osteogenesis but
also in early chondrogenesis in mice [35–37], whereas adipogenesis
is inhibited by activation of the Shh signaling [28,38]. Expression
and activities of GLI1/2 proteins in human ASC tri-lineage differentia-
tion programs have not been described.
The current study aims to investigate whether the mechanism of
activation of Gli1 and Gli2 (Gli1/2) proteins has similarities regardless
of signaling pathway evoking that. In answering this question, we ex-
amine SU6668 as a small molecule inhibitor able to prevent activation
of Gli1/2 proteins in both Shh and TGF-β signaling pathways in an
Ulk3 dependent manner. Finally, we provide novel data in the ﬁeld ofstem cell biology relating to possible roles of Shh signaling and GLI1/2
proteins in ASC differentiation programs.
2. Materials and methods
2.1. Ethic statement
Donors of the primary cells provided written informed consent to
participate in this study in accordance with the approval for research
with human materials No 159 from 14th of February, 2013 by Ethics
Committee of National Institute for Health Development, Tallinn, Estonia.
2.2. Proteins and chemicals
FLAG-tagged ULK3 and GLI2, Shh and His-tagged ULK3-Ubi proteins
were puriﬁed as previously described [6,39,40]. SU6668 was dissolved
in DMSO (both from Sigma-Aldrich, Steinheim, Germany) and stored
at −70 °C prior use. Human recombinant TGF-β1 and TGF-β3 were
purchased from PeproTech (Rock Hill, NJ, USA). Human insulin, dexa-
methasone (DEX), IBMX, indomethacin and ascorbate-2-phosphate
were purchased from Sigma-Aldrich, while ITS supplement was
purchased from Gibco, Invitrogen (Carlsbad, CA, USA).
2.3. Cell culture
Peripheral blood mononuclear cells (PBMCs) and human ASCs were
isolated and characterized as previously described [41]. The donors of
primary cells are described in Supplementary Table 1. Freshly isolated
PBMCswere frozen inD-MEM containing 1 g/L glucose (Gibco), supple-
mented with 50% of Fetal Bovine Serum (FBS) (PAA, Pasching, Austria)
inactivated at 56 °C for 30 min (HI-FBS) and 10% DMSO and stored in
liquid nitrogen prior to use. The C3H10T1/2 cell line was a generous
gift from Prof. Rune Toftgård's lab (Centre for Nutrition and Toxicology,
Karolinska Institute, Sweden). The MDA-MB-231 and 3T3-L1 cell lines
were purchased from ATCC. MDA-MB-231 and 3T3-L1 cells were prop-
agated in D-MEM containing 4.5 g/L glucose (Gibco) supplemented
with 10% FBS and 1% penicillin/streptomycin mix (PEST) (Gibco).
C3H10T1/2 and ASCs were propagated in D-MEM containing 1 g/L
glucose supplemented with 10% of HI-FBS and 1% PEST. The cells were
grown at 37 °C and 5% CO2. All treatments of the cells except inductions
of ASCs towards chondrocytes were conducted in the respective base
growth medium supplemented with 3% of FBS or HI-FBS, 1% PEST,
12 nM Shh or 10 ng/ml of TGF-β3 and different concentrations
of SU6668, if indicated. Adipogenic differentiation was induced by
10 μg/ml of human insulin, 1 μM dexamethasone, 0.5 mM IBMX and
10 μM indomethacin. Chondrogenic differentiation was conducted in
DMEM-high glucose containing 10 ng/ml of TGF-β1, 1× ITS supple-
ment, 100 μM ascorbate-2-phosphate, 1 μM DEX and 1% PEST. Media
were replenished every 2 d.
2.4. Alkaline phosphatase activity
C2H10T1/2 cells were washed with PBS and lysed in Lysis Solution
(Tropix, Bedford MA, USA). Alkaline phosphatase (AP) activity
was measured using CSPD substrate with Sapphire-II™ Enhancer
(Invitrogen) and Genios Pro combined ﬂuoro-and luminometer
(Tecan Group Ltd., Männedorf, Switzerland). Total protein concentra-
tions were measured using BCA Protein Assay kit (Pierce Biotechnology
Inc., Rockford, IL, USA) and used for normalization of AP activity values.
2.5. Over-expression studies
Synthetic Negative siRNA (Silencer Negative Control 2, Neg. siRNA),
Silencer® Select siRNAs S89965 and S89966 against mouse Ulk3 and
S24886 and S24887 against human ULK3were purchased from Ambion
(Austin, TX, USA). Synthetic siRNAs were delivered to cells using
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transfected with 20 nMof siRNAs. Initial reverse and 24 h later forward
transfection procedures were conducted using the same amounts of
siRNAs and transfection reagent. ASCs were transfected with 10 nM
siRNAs using forward transfection protocol. The cells were treated
with DMSO, SU6668 or/and 12 nM Shh or 10 ng/ml TGF/β1 24 h after
forward transfection. MDA-MB-231 cells were transfected with
constructs encoding human FLAG-tagged GLI2, mouse GFP-tagged
Gli2, pcDNA3.1 or pmax-GFP (Lonza Inc.) using Lipofectamine 2000
(Invitrogen) [6,40]. To measure transfection efﬁciency, the cells were
ﬁxed in 4% PFA for 30 min, washed with PBS and analyzed using Accuri
C6 ﬂow cytometer.
2.6. Western blot
Western blot (WB)was performed as previously described [41]. WB
analyses were done using 40–60 μg of total protein per lane. All
immuno-blotting assays were performed at least in three replicates
and representative images are shown. Commercially available antibod-
ies and their dilutions are listed in Supplementary Table 2. Gli2 AF3635
antibody has been described previously [7]. The speciﬁcity of Gli2
antibodies was tested and representative images are shown in
Supplementary Fig. 1A–C. Runx2 antibody was generated in Labas Ltd.
(Tartu, Estonia) against a peptide STLSKKSQAGASELG and used in dilu-
tion 1:2000. WB images were quantiﬁed using ImageQuant software.
2.7. In vitro kinase assay and statistical analysis
In vitro kinase assay and statistical analysis were performed as
described [6]. IC50, Km and Ki values were calculated using GraphPad
Prism software.
2.8. Immunocytochemistry
Primary cilia and nuclei of ASCswere stained as previously described
[42] using antibodies against acetylated tubulin (Sigma-Aldrich), Alexa
Fluor 568 goat anti-mouse IgG (Invitrogen), and Mounting Medium
with DAPI (Abcam). The cells were visualized using ﬂuorescent micro-
scope Olympus BX61 with UPLan SApo 40× objective.
2.9. Nuclear extract preparation
Nuclear and cytoplasmic extracts were prepared using NE-PER®
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientiﬁc).
Approximately 40 μg of the extracts was used for WB analysis.
2.10. Quantitative real time PCR
Quantitative real time PCR (qPCR) was performed as described [41].
The data of qPCR analyses are expressed as the normalized with Hprt or
GAPDH average means ± S.D. of three measurements obtained from at
least three independent experiments. Expression of genes demonstrat-
ing Ct values above 37 were considered as undetectable. The primers
used are listed in Supplementary Table 3.
3. Results
3.1. SU6668 inhibits ULK3 kinase activity in vitro
ULK3 is an active serine/threonine kinase able to phosphorylate it-
self and GLI proteins [40]. It has been previously shown that a tyrosine
kinase inhibitor SU6668 can physically interact with ULK3 in a chro-
matographic pull-down assay [23]. In order to test, whether SU6668 is
able to inhibit ULK3 kinase activity, bacterially expressed and puriﬁed
His-tagged ULK3 protein was tested in the in vitro kinase assay in thepresence of 1 or 10 μM SU6668. SU6668 inhibited ULK3 autophospho-
rylation activity in a concentration dependent manner (Fig. 1A).
In order to determine the Ki of SU6668 for ULK3, ﬁrst the Km of ATP
towards bacterially puriﬁedULK3wasmeasured and found to be 3.2 μM
under these conditions (Fig. 1B). Next, increasing concentrations of
SU6668 were used in the presence of 10 μM ATP in the in vitro kinase
assay (Fig. 1C). Under these conditions, SU6668 was able to inhibit the
ULK3 autophosphorylation activity with an IC50 of 0.6 μM. The calculat-
ed Ki of SU6668 for ULK3 was found to be approximately 0.2 μM.
In order to exclude tag-speciﬁc phenomena and verify the effect of
SU6668 using other ULK3 substrates, over-expressed and immuno-
puriﬁed FLAG-tagged ULK3 and GLI2 proteins were subjected to
in vitro kinase assay in the presence of 2 μMATP and SU6668. Phosphor-
ylation of GLI2 by ULK3 was completely inhibited by 10 μM SU6668;
however, some residual catalytic activity of ULK3 was detectable in
the presence of 1 μM SU6668 (Fig. 1D, left panel). The presence of the
proteins tested in the in vitro kinase assay was conﬁrmed by WB
(Fig. 1D, right panel). These data demonstrate that SU6668 is an efﬁcient
inhibitor of ULK3 kinase in the in vitro kinase assay.
3.2. SU6668 inhibits the Shh signal transduction
Since Ulk3 is able to modulate the activity of Gli proteins and to in-
teractwith SU6668, the effects of SU6668 on the Shhpathway execution
was tested in two Shh-responsive mouse cell lines C3H10T1/2 and 3T3-
L1. Shh stimulates differentiation of C3H10T1/2 toward osteoblasts
without signiﬁcant increase in proliferation [29,33]. In contrast, pre-
adipocytes 3T3-L1 demonstrated increased proliferation rate in
response to Shh (Supplementary Fig. 1D).
C3H10T1/2 and 3T3-L1 cells were treated with Shh and/or 5, 10 or
20 μM SU6668 for 42 h. Expression levels of Gli1, Ptch1, Gli2 and Ulk3
were analyzed by qPCR (Fig. 2 and Supplementary Fig. 2, for C3H10T1/
2 and 3T3-L1, respectively). SU6668 alone had no signiﬁcant effect on
expression ofGli1, Ptch1 andGli2 genes. Expression ofUlk3was elevated
approximately 1.5–2 times in the presence of 20 μM SU6668 (Fig. 2A d
and Supplementary Fig. 2A d).
Shh pathway transcriptional targets Gli1 and Ptch1 became strongly
induced in the Shh-stimulated cells: more than 100 and 30 times above
the control, respectively. In order to synchronize data obtained from
independent experiments, expression levels of Gli1 and Ptch1 in the
cells treated with Shh and DMSO were set as 100%, and the data from
samples treated with Shh and SU6668 were calculated relative to this
(Fig. 2A a, b). SU6668 inhibited activation of Gli1 and Ptch1 expressions
in a concentration dependent manner. In response to Shh, the levels of
Gli2 and Ulk3 transcripts increased approximately 3 and 1.5 times,
respectively (Fig. 2A c, d). In contrast toGli1 and Ptch1, expression levels
of Gli2 and Ulk3 were not signiﬁcantly down-regulated by SU6668.
Along with RNA analysis, Gli1 and Gli2 protein levels were analyzed
by WB (Fig. 2B and Supplementary Fig. 2B). Shh stimulated an increase
of Gli2 protein level that correlatedwith up-regulation ofGli2mRNA ex-
pression (Figs. 2B, upper panel, lanes 1 and 4 and A c). Nevertheless, the
levels of Gli2 protein andmRNA did not correlate in the SU6668-treated
cells. The level of Gli2mRNAwas similar in the cells treated with either
10 or 20 μMSU6668 alone or combinedwith Shh (Fig. 2A c). In contrast,
cells treatedwith Shh and SU6668 expressed lessGli2 protein compared
with the cells treated only with SU6668 (Fig. 2B, upper panel, lanes 3, 6
and 7). Generally, the levels of Gli2 protein, but not mRNA, correlated
with the levels of Gli2 transcriptional target Gli1 in the cells treated
with SU6668 and Shh (Fig. 2A a). The speciﬁcity of Gli2 antibodies was
tested using C3H10T1/2, MDA-MB-231 and peripheral blood mononu-
clear cells (PBMCs) of mouse and human origin. In contrast to other
cells analyzed, PBMCs do not express Gli2 mRNA, but express other
components of the Shh signaling pathway (Supplementary Fig. 1A).
Gli2FL migrating at approximately 165–170 kDa was detected using
immuno-blotting in C3H10T1/2 and MDA-MB-231 cells but not in
PBMCs (Supplementary Fig. 1B–C).
Fig. 1. SU6668 inhibits ULK3 catalytic activity in vitro. (A) Bacterially expressed and puriﬁedHis-taggedULK3 proteinwas subjected to in vitro kinase assay in the presence of 2 μMATP and
vehicle or SU6668. The presence of ULK3 proteinwas veriﬁed byWB. (B) His-taggedULK3 proteinwas subjected to in vitro kinase assay in the presence of indicated concentrations of ATP.
TheMichaelis–Menten curvewas built using levels of ULK3 autophosphorylation activity normalizedwith amount of ULK3 protein identiﬁed by Coomassie staining (both quantiﬁed using
ImageQuant software). (C) ULK3 protein was subjected to in vitro kinase assay in the presence of 10 μM ATP. Different concentrations of SU6668 were included into each reaction. The
intensity of ULK3 autophosphorylation and the amount of ULK3 protein identiﬁed by Coomassie staining were quantiﬁed using ImageQuant software. The normalized level of ULK3
autophosphorylation activity in the presence of vehicle was set as 100%. (D) GLI2 and ULK3 were over-expressed and immuno-puriﬁed using a resin conjugated with FLAG antibody.
The puriﬁed proteins were mixed and subjected to in vitro kinase assay (left panel). The proteins were veriﬁed by WB (right panel).
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protein was undetectable in the absence of Shh (Fig. 2B, middle panel).
Similarly to Gli1mRNA and Gli2 protein, Gli1 protein was up-regulated
in response to Shh and down-regulated in the presence of SU6668.
It has been shown that stimulation of cells with Shh leads to rapid
stabilization and nuclear translocation of Gli2FL [7]. Gli2FL protein was
examined by WB in whole cell and nuclear extracts (WCE and NE, re-
spectively) of C3H10T1/2 cells treated with 20 μM SU6668 and/or Shh
for 2 h (Fig. 2C). The amount of Gli2FL increased in response to Shh in
WCE and NE signifying physical stabilization and nuclear translocation
of Gli2FL. SU6668 inhibited the positive effect of Shh on Gli2FL indicat-
ing that one of the possible mechanisms of SU6668 action may be
prevention of stabilization and/or nuclear transport of Gli2FL. In order
to conﬁrm the visual observations, Gli2 and Lamin B and/or GAPDH
immuno-blotting images obtained from 3 independent experiments
were quantiﬁed. Gli2 protein levels were normalized using Lamin B or
GAPDH protein levels and set as 1 in the control sample. Data from
other samples were calculated relative to that (Fig. 2D). The level of
Gli2 protein increased approximately 1.6 times in response to Shh in
WCE and NE and remained similar to the control level in the presence
of SU6668.
3.3. SU6668 acts via Ulk3
It has been shown that SU6668 induces G2/M phase arrest of HeLa
cells [23]. Block of cell cycle in G2/M phase and subsequent inhibitionFig. 2. SU6668 hinders Shh signaling in C3H10T1/2 cells. (A, B) C3H10T1/2 cells were treated
by qPCR and normalized by the level of HprtmRNA expression. The normalized level of the re
presented as an average mean ± S.D.; *—p b 0.05, ***—p b 0.001, n = 4. (C) C3H10T1/2 cells
extract preparation (WCE and NE, respectively). The proteins were analyzed by WB. Gli2 was
images were quantiﬁed. Gli2 protein levels were normalized with Lamin B and/or GAPDH lev
mean ± S.D.; *—p b 0.05, **—p b 0.01, n = 3.of primary cilia formation may negatively inﬂuence the Shh pathway
execution. Therefore, the cell cycle proﬁle was analyzed in C3H10T1/2
and 3T3-L1 cells treated with Shh and/or different concentrations of
SU6668. No signiﬁcant change in G2/M phase of cell cycle was detected
(Supplementary Fig. 2D). It has been shown that several other kinases
apart of Ulk3 participate in regulation of Gli proteins, and SU6668 is
not speciﬁc inhibitor for Ulk3 [22,23]. In order to examine, whether
the effects of SU6668 on Gli proteins are mediated via Ulk3 kinase, we
suppressed Ulk3mRNA expression in C3H10T1/2 and 3T3-L1 cells. For
Ulk3 RNAi, the previously described pSUPER constructs encoding Ulk3
shRNAs [6] and Ulk3-speciﬁc synthetic siRNAs S89965 and S89966
(Ambion) were used. C3H10T1/2 cells were electroporated with the
constructs encoding Ulk3 shRNAs, and 3T3-L1 cells were transfected
with Ulk3 synthetic siRNAs using Lipofectamine. The obtained results
are depicted in Fig. 3 and Supplementary Fig. 3 for 3T3-L1 and
C3H10T1/2 cells, respectively.
Ulk3 and Gli2 mRNA expression levels were measured using qPCR
and set as 1 in the cells transfected with Neg. siRNA (Fig. 3A a, b). Ulk3
mRNA levels measured at 24 h post-transfection were reduced approx-
imately 45% and 64% in the 3T3-L1 cells transfected with Ulk3 siRNA1
and siRNA2, respectively. The levels of Gli2 mRNA measured in the
same cells were reduced approximately 62% and 73%. Cells transfected
with Ulk3 siRNAs twice expressed approximately 70% less Ulk3 and
Gli2 transcripts. Initial low Ulk3 and Gli2mRNA levels increased gradu-
ally during propagation of cells reaching and even exceeding the control
levels. Similar tendencywas observed in C3H10T1/2 cells; however, theas indicated for 42 h. The levels of expression of Gli1, Ptch1, Gli2 and Ulk3were analyzed
spective gene mRNA in the control sample treated with DMSO was set as 1. The data are
were treated as indicated for 2 h. The cells were split for whole cell extract and nuclear
detected using Gli2 G-20 (B) or AF3635 (C) antibodies. (D) Gli2, Lamin B and/or GAPDH
els and set as 1 in the control cells treated with DMSO. Data are presented as an average
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Fig. 3. SU6668 inhibits Shh dependent up-regulation ofGli1 viaUlk3. (A, B, C, D) 3 T3-L1 cellswere transfectedwithUlk3-speciﬁc Silencer®Select siRNAs S89965 and S89966using reverse
followed by forward procedures resulted in single and double transfection, respectively. The cells were treatedwith DMSO, 20 μM SU6668 and Shh, if speciﬁed, and incubated during the
indicated periods of time. (A) Levels of Ulk3 (a) and Gli2 (b) transcripts were measured by qPCR, normalized with HprtmRNA expression level and set as 1 in the cells transfected with
Negative siRNA. The data from samples transfected with Ulk3-speciﬁc siRNAs were calculated relative to the negative control. (B) The cells were subjected to WB analysis after the
indicated periods of time of the siRNA delivery using Gli2 G-20 antibody. (C) The cells subjected to double transfection by siRNAs were treated with Shh, DMSO or SU6668 for 24 and
48 h. Gli1mRNA expression level was measured by qPCR, normalized with Hprt expression level and set as 1 in the respectively transfected control sample treated with DMSO. Gli1
mRNA expression level in the Shh-treated samples were calculated relative to the control. The data are presented as fold of induction of Gli1mRNA level. Data of qPCR analyses are
presented as an average mean ± S.D.; *—p b 0.05, **—p b 0.01, ***—p b 0.001, n = 3. (D, a–b) Lysates of 78 h post-transfectional and 30 h post-inductional cells were analyzed by
WB. Gli1 and Lamin B imageswere quantiﬁed. The normalized Gli1 protein level in the control cells treatedwith DMSO and Shhwas set as 100%. Data from other samples were calculated
relative to that. Data are presented as an average mean ± S.D.; **—p b 0.01, n = 4.
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48 h after transfection) probably due to the single electroporation
procedure applied (Supplementary Fig. 3A a–b).
Gli2 protein level was assessed by WB. Correlation between the
levels of Gli2 protein and mRNA was observed with some temporal
shift. Although 24 h post-transfectional cells contained similar amounts
of Gli2 protein, cells transfected twice with Ulk3 siRNAs demonstrated
reduced levels of Gli2 protein (Fig. 3B). Gli2 protein level gradually
increased in the cells transfected with Ulk3 siRNAs during propagation
exceeding that of control 96 h after initial transfectionwhich correlated
with up-regulation of Gli2mRNA level.Afterwards, 48 h post-transfectional cells expressing the lowest levels
of Gli2 and Ulk3 were treated with Shh, 20 μM SU6668 or DMSO for 24
and 48 h. Gli1mRNA levels were measured by qPCR. For the each partic-
ular set of data, Gli1 expression level was considered as 1 in control cells
treated with DMSO and the data from other respectively transfected but
differently treated samples were calculated as fold of Gli1mRNA induc-
tion over control. SU6668 alone had no signiﬁcant effect on Gli1mRNA
expression (data not shown). In response to Shh,Gli1mRNA level initially
increased approximately 75 times in the control cells and 32 and 22 times
in the cells transfectedwithUlk3 siRNAs (Fig. 3C). However, compared to
the control cells, Gli1mRNA level became similar or even higher in the
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transfection, 48 hpost-inductionwith Shh). As the above-described anal-
yses revealed, Gli2mRNA and protein levels had been also increased at
this time point in these cells (Fig. 3A b and B) that may be associated
with increased transcriptional activity of Gli2. Up-regulation of Gli2
may explain higher Gli1mRNA expression levels in the cells transfected
with Ulk3 siRNAs and induced by Shh for 48 h. SU6668, added together
with Shh, was active in the control cells but could not effectively inhibit
Gli1mRNA expression in the cells with reduced levels of Ulk3 and Gli2
(Fig. 3C). However, low negative effects of SU6668 on Shh dependent ac-
tivation of Gli1 in the case of restored levels of Gli2 observed 96 h after
Ulk3 RNAi may be caused by possible instability of SU6668 in cell culture
conditions during 48 h of incubation and consequently, insufﬁcient con-
centration of active SU6668 per Gli2/Ulk3 complex in the cells expressing
increased levels of Gli2 protein.
In order to conﬁrm the observations of the impact on Gli1 mRNA
level, Gli1 protein was analyzed by WB in the cells transfected twice
with Ulk3 or Neg. siRNAs and treated with Shh and/or 20 μM SU6668
for 32 h. Gli1 and Lamin B immuno-blotting images obtained from
four independent experiments were quantiﬁed. Gli1 protein level was
normalized with Lamin B and set as 100% in control sample. Data from
other samples were calculated relative to this. Increase of Gli1 protein
was stronger in the control cells, and SU6668 was not effective in the
cells transfectedwithUlk3 siRNAs (Fig. 3D). Similar results were obtain-
ed analyzing levels of Gli1mRNA and protein in another experimental
model (Supplementary Fig. 3C–D).
3.4. Regulation of GLI1/2 by TGF-β and SU6668 in human immortalized
breast cancer cells
Apart from Shh, TGF-β regulates expression and transcriptional ac-
tivity of GLI1/2 in a SMAD3, TCF4 and β-catenin dependent mannerFig. 4. TGF-β induced positive regulation of GLI2 protein is inhibited by SU6668 inMDA-MB-231
of TGF-β3 during the indicated periods of time. (A) GLI2 (a), ULK3 (b) and GLI1 (c) mRNA lev
control cells treated with DMSO (indicated by baseline on the panels a and b). The level of GLI1
as an average fold of induction of gene expression level over a control ± S.D. (B) Whole cell l
(C) MDA-MB-231 cells were transfected either with plasmids encoding mouse mGli2 or hum
The data are presented as an average fold of induction ± S.D. of the particular gene expres
(A, C) *—p b 0.05, **—p b 0.01, ***—p b 0.001, n = 3, ND — not detected.[18,19]. In order to explore the effects of SU6668 on regulation of GLI2
in the context of TGF-β pathway, immortalized breast cancer cells
MDA-MB-231 were used. These cells have been previously reported to
express GLI1, GLI2 and PTCH1 and respond to TGF-β1 treatmentwith in-
creased levels of GLI2 and GLI1mRNAs [18,43]. MDA-MB-231 cells were
treated with TGF-β3, 20 μM SU6668 or DMSO for 4, 8, 12 and 24 h. The
expression levels of “Shhmediators” GLI2, GLI1 and ULK3 and “classical”
TGF-β target genes SMAD7, PAI1, CTGF and SNAI1 were measured by
qPCR and normalized to 1 in the cells treated with DMSO (Fig. 4A and
Supplementary Fig. 4).
SU6668 had no statistically signiﬁcant effect on expression of
most genes analyzed except ULK3 and SNAI1 (data not shown and
Supplementary Fig. 4A a, b). ULK3 expression gradually increased
during exposure of cells to SU6668 reaching almost 2-fold induction
within 24 h. Expression of SNAI1 was down-regulated by SU6668
approximately 65%.
TGF-β stimulated expression of all analyzed genes, however, the
dynamic of up-regulation and effects of SU6668 varied for different
genes (Fig. 4A and Supplementary Fig. 4A). Signiﬁcant up-regulation
of SMAD7, PAI1, CTGF and SNAI1 was observed already within 4 h of
TGF-β treatment. Expression of GLI2 increased approximately 3 times
during 6 h of TGF-β treatment and afterwards decreased gradually but
remained elevated over control.
SU6668 did not signiﬁcantly inhibit TGF-β induced up-regulation of
GLI2, SMAD7, PAI1 and CTGF. It had statistically insigniﬁcant positive
effect on GLI2mRNA expression during prolonged propagation of cells
in the presence of TGF-β (Fig. 4A a). Expression of ULK3 was induced
12 h after activation of TGF-β signaling (Fig. 4A b). Increase of ULK3
transcription was accompanied by augmentation of GLI2 protein level
(Fig. 4A b and B, respectively). In contrast to “classic” TGF-β target
genes, up-regulation of ULK3 expression was inhibited by SU6668 that
correlatedwith depleted level of GLI2 protein in the respectively treatedcells. (A, B)MDA-MB-231 cells were treatedwith DMSOor 20 μMSU6668 in the presence
els were analyzed by qPCR, normalized with GAPDH expression level and set as 1 in the
mRNA expression in the cells treated with TGF-βwas set as 100%. The data are presented
ysates were subjected to WB analysis. GLI2 protein was detected using AF3635 antibody.
an hGLI2. The levels of the indicated gene expression were measured by qPCR after 18 h.
sion level over a control level measured in the cells transfected with an empty vector;
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treatment with TGF-β and SU6668 similarly as it was observed in the
case of SU6668 alone (Fig. 4A b and Supplementary Fig. 4A a). Also,
TGF-β dependent induction of SNAI1 expression was down-regulated
by SU6668 suggesting a positive correlation between GLI2 transcrip-
tional activity and expression of SNAI1.
Contrary to the previously published reports, GLI1 expression was
under the detection limit in native MDA-MB-231 cells. In order to com-
pare GLI1mRNA levels induced by TGF-β in the presence or absence of
SU6668, expression level of GLI1was set as 100% in the samples treated
with TGF-β and the data from other samples were calculated relative to
that. In contrast to GLI2, GLI1 expression was signiﬁcantly down-
regulated by SU6668 24 h after treatment with TGF-β, as it was ob-
served for ULK3 at 12 h (Fig. 4A c).
WB analysis of cells treatedwith TGF-β combinedwith either DMSO
or SU6668 showed similar levels of primarymediators of TGF-β signal—
SMAD2/3 and activated form of SMAD2 phosphorylated at serine resi-
dues 465/467, as well as CTGF (Fig. 4B). However, GLI2 protein was
not up-regulated in the presence of SU6668.
Increase of ULK3mRNA expression correlated with up-regulation of
GLI2 protein level at the respective timepoint. These data suggest a pos-
sible involvement of GLI2 in regulation of ULK3 gene expression. To test
this hypothesis, mouse and human Gli2 were over-expressed in MDA-
MB-231 cells for 16 h. The levels of ULK3, PTCH1, GLI1 and GLI2
mRNAsweremeasured by qPCR (Fig. 4C). GLI2 of human origin demon-
strated slightly higher transcriptional activity than mouse Gli2 in MDA-
MB-231 cells. Gli2 could up-regulate GLI2 expression, either directly or
via induction of GLI1. Over-expressed Gli2 proteins could not induce
PTCH1 expression in MDA-MB-231 cells, whereas ULK3 expression
was induced approximately 2 times suggesting that GLI2 may play a
co-activator role in regulation of ULK3 gene expression. Lower increase
of ULK3 expression in response to over-expressed Gli2 proteins may be
caused by poor transfection efﬁciency of MDA-MB-231 cells (approxi-
mately 18%) (Supplementary Fig. 4C).
3.5. ULK3 controls GLI1/2 proteins in human ASCs
ASCs represent heterogeneous populations of cells able to respond
to variable stimuli by expressing different lineage-speciﬁc markers
and differentiate, at least under in vitro conditions, towards adipocytes,
chondrocytes and osteoblasts [24]. Since human ASCs have not been
systematically described in respect of the canonical Shh pathway, ex-
pression of the mediators of Shh signaling (SHH, PTCH1, SMO, ULK3,
GLI2 and GLI1) was examined by RT-PCR in ASCs isolated from four do-
nors. All genes except SHH were expressed in ASCs (Fig. 5A). Very low
level of SHH expression was detected only in one sample suggesting
that generally ASCs are not subjected to autocrine regulation by Shh.
Also, ASCs were stained using an antibody against acetylated tubulin
to visualize primary cilia required for the canonical Shh signal transduc-
tion. Approximately 50% of ASCs displayed primary cilia (Fig. 5B).
GLI proteins can be activated via Shh and TGF-β signaling axes. In
order to examine canonical and non-canonical activation of GLI1/2 pro-
teins in ASCs, the cells were treatedwith Shh or TGF-β1 for 18 h and the
levels of expression of GLI1, PTCH1, GLI2 and ULK3 were examined by
qPCR. The cells responded to Shh treatment by increased level of GLI1
and PTCH1mRNA, whereas GLI2mRNA level was elevated in response
to TGF-β (Fig. 5C). In all cells analyzed, TGF-β activated GLI1 transcrip-
tion approximately 2.2 times stronger than Shh did probably due to as-
sociated activation of GLI2. Up-regulation of GLI1 and PTCH1 expression
in response to Shh, presence of primary cilia and expression of the key
mediators of the Shh signaling together strongly indicate a subpopula-
tion of ASCs possessing the functional Shh pathway.
Next, ULK3was assessed as a regulator of GLI1/2 in ASCs.ULK3mRNA
expression was inhibited approximately 65 and 77% using two synthetic
siRNAs (Fig. 5D a). Concurrently, GLI2 and GLI1mRNA and protein levels
were reduced in these cells (Fig. 5D b–d). Of note, in contrast to themouse cells used, the level of GLI1 protein was high enough to be detect-
ed byWB in native ASCs (Fig. 5D d). Afterwards, 24 h post-transfectional
ASCs were treated with TGF-β1 for additional 24 h and expression of
ULK3, GLI2 and GLI1 were analyzed by qPCR. Gene expression levels in
control cells transfected with Neg. siRNA were set as 1, and data from
other samples were calculated relative to this (Fig. 5E a–c). The levels of
ULK3 transcripts remained reduced 48 h post-transfection in cells treated
with ULK3 siRNAs. GLI2 expression was induced in response to TGF-β
treatment approximately 1.7 times in all cells analyzed. However, the ab-
solute levels of GLI2 transcripts remained lower in the TGF-β1 treated
cells transfected with ULK3-speciﬁc siRNAs and expressed lower levels
of GLI2mRNA and protein at treatment initiation. Substantial increase
of GLI2 protein level in response to TGF-β1 was observed only in ASCs
transfectedwithNeg. siRNA (Fig. 5F a, upper panel and b).GLI1 transcrip-
tionwas induced by TGF-β1 approximately 7.3, 2.6 and 2.4 times in ASCs
transfected with Neg. siRNA, ULK3 siRNA1 and siRNA2, respectively
(Fig. 5E c). Similarly to GLI2, signiﬁcant increase of GLI1 protein in re-
sponse to TGF-β treatment was observed only in the cell transfected
with Neg. siRNA (Fig. 5F). Taken together, these data indicate that ULK3
does not participate in the TGF-β signaling cascade but is required for sta-
bility of GLI2 and GLI1 proteins.
3.6. SU6668 inhibits osteo- and chondrogenic differentiation of ASCs
In order to explore the effect of SU6668 on GLI1/2 proteins in primary
human cells, ASCs were treated with Shh or TGF-β1 in the presence of
20 μM SU6668 or DMSO. GLI1 and GLI2 expression levels were assessed
by qPCR and the respective protein levels by immuno-blotting (Fig. 6A
a–c). In order to synchronize the data obtained from different experi-
ments, GLI1 expression level in control ASCs treated with Shh was set
as 100% and data from other samples were recalculated relative to this.
TGF-β stimulated GLI2 mRNA expression was not suppressed by
SU6668, as it was observed inMDA-MB-231 cells (Figs. 6A a and 4A a, re-
spectively). Also, SU6668 had no negative effect on Shh-induced GLI1
mRNA expression but inhibited expression of GLI1 up-regulated in re-
sponse to TGF-β signaling (Fig. 6A b). However, immuno-blotting analy-
sis showed that induction of GLI1 and GLI2 proteins in response to Shh or
TGF-βwas restrained by SU6668 (Fig. 6A c). The behavior of GLI1 in ASCs
challenged with Shh and SU6668 resembled that of Gli2 in mouse
C3H10T1/2 and 3T3-L1 cells:GLI1mRNAand protein levels did not corre-
late in ASCs treatedwith Shh and SU6668 similarly to non-correlatedGli2
mRNA and protein levels in the respectively treated mouse progenitor
cells (Figs. 6A b and c 1st panel, 2A c, B 1st panel, Supplementary
Fig. 2A c and Supplementary Fig. 2B 1st panel). Similar phenomenon
was observed in the case of GLI2 and TGF-β: GLI2 transcription was not
inhibited by SU6668, but up-regulation of GLI2 protein and as a result
its transcriptional activity was restrained. These data reveal that effects
of SU6668 resemble effects of ULK3 RNAi in the case of GLI1/2 activation:
neither SU6668 nor ULK3 knockdown interrupts Shh or TGF-β signaling
cascades but both reduce stability of the de novo generated GLI1 and/or
GLI2 proteins (Fig. 5 E–F and 6A). The difference between ULK3 RNAi
and SU6668 treatments becomes apparent in the case of regulation of
basal GLI proteins: SU6668 has no signiﬁcant effect on their expression,
but ULK3 knockdown leads to decrease of basal GLI1/2 levels (Fig. 5D
and 6A c). This difference may be explained by possible dual role of
ULK3: SU6668 inhibits only catalytic activity of ULK3 kinase, whereas
both regulatory and catalytic activities are disrupted by ULK3 RNAi.
To study the effects of SU6668 on tri-lineage differentiation of
human ASCs, the respective treatments were conducted for 4 or 6 d,
andWCEswere analyzed using immuno-blotting. Shh triggered expres-
sion of all osteogenic differentiation markers tested (both RUNX2 iso-
forms, OPN and BGLAP) and GLI1 (Fig. 6B a). Chondrocytes speciﬁc
proteins COL2, SOX9, MMP13 as well as GLI1 and GLI2 were induced
in response to prolonged exposure to TGF-β1 containing media
(Fig. 6B b). SU6668 inhibited expression of the chondro- and osteo-
lineage speciﬁc markers in ASCs, as it was observed in C3H10T1/2
Fig. 5. ULK3 participates in regulation of GLI1/2 transcriptional activators in ASCs. (A) Expression of genes encodingmediators of the Shh signaling pathway was analyzed using RT-PCR in
ASCs isolated from four donors. (B) Primary cilia (red) and nuclei (blue) were stained using antibody against acetylated tubulin and DAPI, respectively. (C) Levels of GLI1 (a), PTCH1
(b), GLI2 (c) and ULK3 (d) mRNAs were measured by qPCR in ASCs stimulated with Shh or TGF-β1. (D) ASCs were transfected with Neg. or ULK3-speciﬁc siRNAs. The levels of ULK3
(a),GLI2 (b) andGLI1 (c) transcripts weremeasured by qPCR; (d) GLI1 and GLI2 proteinswere analyzed by immuno-blotting. (E) ASCswere transfectedwith Neg. orULK3-speciﬁc siRNAs
and 24 h later treated with TGF-β1 for 24 h. The levels of ULK3 (a), GLI2 (b) and GLI1 (c) transcripts weremeasured by qPCR. (F) (a) GLI2 and GLI1 proteins were analyzed byWB in cells
transfectedwith Neg. or ULK3-speciﬁc siRNAs and induced with TGF-β1 for 30 h. GLI2, GLI1 and GAPDH imageswere quantiﬁed. Normalized GLI2 (b) and GLI1 (c) protein levels were set
as 1 in cells transfected with Neg. siRNA. Data of qPCR and quantiﬁedWBs are presented as an average mean ± S.D.; *—p b 0.05, **—p b 0.01, ***—p b 0.001, n = 3.
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Fig. 6. SU6668 prevents de novo generation of GLI1 and GLI2 proteins in ASCs. (A) ASCswere treatedwith Shh, TGF-β1 and 20 μMSU6668 or DMSO. (a) Levels of GLI2 and GLI1 transcripts
were measured using qPCR. Data are presented as an average mean ± S.D.; *—p b 0.05, **—p b 0.01, ***—p b 0.001, n = 4. (b) WCEs were subjected to immuno-blotting analysis.
(B) ASCs were treated with Shh (a), chondrogenic cocktail containing TGF-β1 (b) or adipogenic cocktail containing insulin, DEX, IBMX and indomethacin (c) in the presence of DMSO
or 20 μM SU6668. GLI1/2 and lineage speciﬁc proteins were analyzed by WB.
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effect of SU6668 was noticeable in the case of the higher molecular
weight RUNX2 isoform that was induced to higher extent by Shh
(Fig. 6B a 3rd panel and Supplementary Fig. 5B–C). In contrast to
osteo- and chondrogenic differentiation programs, adipogenic differen-
tiation of ASCs was accompanied by down-regulation of GLI1/2 protein
and was not inhibited by SU6668 (Fig. 6B c).
4. Discussion
Regulation of Gli1/2 transcription factors is one of the cross-talking
points of ShhandTGF-β signalingpathways.However,mechanistic differ-
ences speciﬁc for these intracellular signaling cascades are obvious: TGF-
β/SMAD axis controls GLI2 transcription, whereas post-translational
regulation of Gli2 protein activity is the central event in the Shh pathway.
In both cases, Gli2 is known to up-regulateGli1 transcription. In this study
we have identiﬁed SU6668 as a small molecular weight modulator of Gli
protein activity and shown that there are common elements in regulation
of Gli1/2 transcriptional activators by TGF-β and Shh.
4.1. SU6668 as an inhibitor of Ulk3 kinase activity and de novo generated
Gli proteins
The existing inhibitors of the Shh pathway mostly target SMO
oncoprotein, the trans-membrane signaling effectors of Shh. However,in many cases the somatic gain-of-function mutations in SMO occur in
human cancers,making SMO inhibitors useless for therapeutic purposes
[21]. Also, the fact that GLI transcription factors may be functioning in-
dependently of the canonical Shh pathway requires development of
novel inhibitors targeting activity of GLI proteins [44–46]. This kind of
inhibitors might be useful in treatment of speciﬁc GLI-dependent
types of cancer. ULK3 has been suggested as a regulator of GLI1/2 tran-
scriptional activators able to interact with the ATP-competitive tyrosine
kinase inhibitor SU6668 [23,40].
Here, SU6668 is demonstrated as an inhibitor of ULK3 kinase activity
in vitrowith Ki of 0.2 μM. Biochemical Ki of SU6668 towards receptor ty-
rosine kinases ranged from 0.008 μM for PDGFR to 2.1 μM for VEGFR2,
and IC50 values for a number of other kinases were at least 10 μM [22].
The observed Ki value indicates that SU6668 is effective inhibitor also
for ULK3.
Our results demonstrate that Gli1/2 transcriptional activators
may be suppressed by SU6668 in different types of cells and inde-
pendently of the signaling cascade involved in their activation.
First, using two mouse cell lines and Ulk3 RNAi approach we have
demonstrated that SU6668 inhibits the Shh pathway execution via
Ulk3, as assessed by analyses of Gli1 and Ptch1 expression induced
in a Gli2 dependent manner. Second, elevated levels of GLI1/2 pro-
teins are down-regulated using SU6668 in ASCs. Third, SU6668
inhibits TGF-β mediated activation of GLI2 protein and subsequent
GLI1 and ULK3 transcription in MDA-MB-231 cells. These ﬁndings
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Interestingly, SU6668 does not inhibit TGF-β mediated transcrip-
tional activation of GLI2 in ASCs or MDA-MB-231 cells as well as Shh
induced expression of GLI1mRNA in ASCs. A similar phenomenon was
observed in Shh dependent up-regulation of Gli2 expression in the
presence of SU6668 in mouse cells. However, Gli1/2 protein levels
were substantially down-regulated in all above-mentioned cases. The
observed negative effect of SU6668 might be explained by inhibition
of post-transcriptional mechanisms regulating translation or stability
of de novo generated Gli1/2 proteins in the context of active Shh or
TGF-β signaling pathways. Themechanism of SU6668 action on activat-
ed GLI1/2 is similar to effects of ULK3 RNAi: activation of GLI2 transcrip-
tionwas not interfered, but the levels of GLI2 protein were not elevated
in response to TGF-β. These results let to assume that SU6668 acts via
ULK3. Also, our Ulk3 RNAi experiments revealed that SU6668 inhibits
Gli proteins via Ulk3. Taken together these data suggest that Ulk3 is re-
quired not only for activation but also for stabilization of endogenous
Gli1/2 proteins. This hypothesis is supported by data showing that
Ulk3 is involved in maintenance of basal Gli2 expression. In view of
the fact that SU6668 is not a very speciﬁc inhibitor of Ulk3, it cannot
be formally ruled out that other kinase(s) regulating Gli1/2 may be
also inhibited.
It is noteworthy that Ulk3mRNA level increased during prolonged
culturing of cells in the presence of SU6668. Because of lack of an
Ulk3-speciﬁc antibody, we failed to examine a correlation between
Ulk3 protein andmRNA levels andmay only speculate that this increase
could be caused by indirect compensatory transcriptional up-regulation
of Ulk3, since our previous work has suggested that Ulk3 kinase is
required for maintenance of cellular homeostasis [6].
4.2. Generation of Gli2ACT
Studies on the dynamics of the Shh pathway activation have
suggested a mechanism of Gli2/3ACT formation: in response to ligand
binding, Gli2/3FL are stabilized and transformed to Gli2/3ACT probably
via yet uncharacterized phosphorylation event [7,12,47]. Our analysis of
Gli2 in whole cell and nuclear extracts also shows that Shh induces
rapid stabilization of Gli2FL and increase of nuclear Gli2FL, where it
probably acts as a transcriptional activator. It is plausible that the
observed nuclear translocation of Gli2FL is a consequence of speciﬁc
phosphorylation resulted in generation of Gli2ACT. Several serine/
threonine kinases, such as PKA, GSK3, CK1 and DYRK2, can directly
phosphorylate Gli2, but the functional consequence of these phosphor-
ylations is connected to processing and degradation of Gli2 [48,49].
Phosphorylation of Gli2 by Ulk3 leads to increase of its transcriptional
activity [40]. Our data show that SU6668 abolishes the Shh-induced
nuclear translocation of Gli2FL and suggest that the nuclear form of
Gli2FL may be the one phosphorylated by Ulk3 and this kind of
phosphorylation is required for Gli2ACT generation.
4.3. Interrelationship between Gli2 and Ulk3 activities
The presentwork has revealed that Ulk3 andGli2 are interconnected
and probably subjected to cross-regulation on transcriptional and/or
post-translational levels. Ulk3 RNAi resulted not only in reduction of
Ulk3 transcripts but also in loss of Gli2 in mouse cells and human
ASCs, whereas TGF-β-induced endogenous or over-expressed GLI2
proteins were associated with induction of ULK3 expression in MDA-
MB-231 cells. These results indicate a possible positive feedback loop
between Gli2 and Ulk3: Ulk3 mediated phosphorylation is required
for stabilization and activation of Gli2, which in turn participates in pos-
itive regulation of Ulk3 transcription. Bioinformatic analysis of 600 bp
of the ULK3 5′UTR revealed at least 3 non-consensus Gli binding
sites: GTCCTCCCA(−591 bp), GGCCTCCCA(−471 bp) and AGCCAC
CCA(−78 bp) (non-consensus nucleotides are underlined), whichmay be functional, since the sites with single substitutions have
activities similar to the consensus site in luciferase reporter assay [50].
Nevertheless, the issue whether the Gli2 protein binds directly to Ulk3
promoter or works in an indirect manner remains to be investigated.
As it has been shown previously, inhibition of Ulk3 expression using
plasmids expressingUlk3-speciﬁc shRNA led to stronger increase of Gli1
mRNA expression in response to Shh than it was achieved in the control
cells after 48 h of treatment [6]. The samephenomenonwas observed in
the present study in two experimental models andmay be explained by
up-regulation of Ulk3 and Gli2 to the levels higher than in the control
cells at late stages of RNAi experiments. However, the present more
detailed analysis has revealed that induction ofGli1 by Shh is attenuated
in the cells with reduced expression levels of Ulk3 and Gli2 at initial
stages of treatment. These results conﬁrm a previously suggested, but
not experimentally tested, model assuming a positive role of Ulk3 in
regulation of endogenous Gli proteins.
4.4. Shh triggers the osteogenic differentiation program in ASCs
ASCs represent a promising tool for cell therapy and regenerative
medicine, areas strictly depending on detailed understanding of the
molecular regulatory mechanisms controlling behavior and fate of
transplanted cells.
The present study shows that human ASCs possess functional Shh
signaling axis. ASCs respond to Shh by increasing the levels of GLI1
and PTCH1 expressions, although the extent of their activation was at
least 10 times lower compared with the mouse cell lines studied. This
may be explained by relatively small and variable fractions of cells
positive for Shh co-receptors PTCH/SMO within the heterogeneous
ASCs isolated from different donors. An interesting point to make from
these experiments is that GLI1 is found to be expressed at levels detect-
able by immuno-blotting in all ASCs analyzed. These data are in contrast
to the mouse cells studied, where Gli1 protein cannot be detected
without challenging the cells with Shh. The level of GLI1 protein was
under the detection limit also in MDA-MB-231 cells even in the case
of TGF-β treatment triggering up-regulation of GLI1mRNA expression.
Contrary to mouse cells, Shh has no signiﬁcant positive effect on GLI2
expression or stability in ASCs that may be effectively induced by TGF-
β. These results raise the possibility that the Shh signaling cascade
may utilize GLI1 instead of GLI2 as a primary transcriptional activator
because of high basal GLI1 expression in ASCs.
TheHh/Gli axis is known to control commitment ofmultipotent cells
towards chondrocyte and osteocyte lineages in mice [28,51]. This study
shows that prolonged exposure to Shh triggers expression of osteocytic
lineage speciﬁc markers in ASCs. These observations suggest Shh co-
receptors PTCH/SMO as possible surface markers for isolation of a
subpopulation of ASCs capable for osteogenic differentiation, which
potentially could be very useful for the branch of regenerativemedicine
involved in treatment of disorders caused by loss of bone tissue.
Treatmentwith SU6668 attenuates both TGF-β induced chondrogenic
and Shh mediated osteogenic differentiation programs. These effects
are consistent with the putative roles of GLI proteins in these differen-
tiation paradigms. In contrast, differentiation of ASCs towards adipo-
cytes was effective in the presence of SU6668. Although we are
aware of the fact that SU6668 is not a very speciﬁc inhibitor of Ulk3,
our results open up possibilities to design novel and more speciﬁc in-
hibitors of Ulk3 kinase and Gli proteins using SU6668 as a starting
compound.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.003.
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